Results 161 to 170 of about 13,073,871 (296)

SPHINX31 acts as a SRPK1 inhibitor targeting the ATR/DNA‐PKcs/CHK1 replicative checkpoint to inhibit cell growth in non‐small cell lung cancer

open access: yesMolecular Oncology, EarlyView.
The kinase SRPK1 directly interacts with the protein TOPBP1 and regulates the pre‐mRNA splicing of WIZ thereby contributing to the activation of the ATR/CHK1 replicative checkpoint in response to replicative stress. This allows cancer cells' genomic stability and survival.
Amani Shreim   +17 more
wiley   +1 more source

Mutant p53R273H disrupts PDPK1 homodimerization and contributes to PDPK1 activation

open access: yesMolecular Oncology, EarlyView.
How mutant p53R273H drives AKT signaling is unclear. We show that p53R273H, but not wild‐type, directly binds PDPK1 via a mutation‐dependent conformational change. This interaction disrupts inhibitory PDPK1 homodimerization and enhances AKT phosphorylation.
Mei Chee Lim   +11 more
wiley   +1 more source

Cultura dell’avidità vs. cultura meridiana nella crisi Xylella: saperi, epistemologie e conflitto nel Sud Salento

open access: yesCambio
This study analyzes the conflict between two opposing epistemic and cultural models: the cultura dell’avidità driven by extractive and speculative logics, and the cultura meridiana rooted in local knowledge and agroecological practices.
Angelo Galiano
doaj  

Giving voice. [PDF]

open access: yesOpen Res Eur
Ivić N.
europepmc   +1 more source

Targeting the EpCAM‐AXL axis to overcome drug resistance in lung cancer

open access: yesMolecular Oncology, EarlyView.
Lung cancer cells often evade therapy by hijacking signaling pathways. We reveal that cleaved EpCAM (sEpCAM) stabilizes the oncogenic protein AXL, driving NF‐κB and STAT3‐mediated chemoresistance. This EpCAM‐AXL axis identifies a high‐risk patient subset with poor prognosis.
Alexa Guerrero‐Alba   +5 more
wiley   +1 more source

Characterization of therapeutic antibodies targeting lymphatic and vascular resistance factor for the treatment of hypervascularized and highly metastatic cancers

open access: yesMolecular Oncology, EarlyView.
LVRF (lymphatic and vascular resistance factor) is a VEGFA splice variant upregulated in response to anti‐angiogenic therapy that fosters tumor adaptation through enhanced vascularization, lymphangiogenesis, and metastatic dissemination. Targeting LVRF with fully human neutralizing antibodies disrupts these processes and limits resistant tumor growth ...
Marion David   +12 more
wiley   +1 more source

Autour des "subaltern studies"

open access: yesCalenda, 2002
7e Journée du Centre d'Etudes de l'Inde et de l'Asie du Sud Mardi 3 décembre 2002 Amphithéâtre de l'EHESS 105, boulevard Raspail, 75006 Paris 9h30: Présentation par Denis MATRINGE (CNRS), directeur du CEIAS.
openaire   +1 more source

Home - About - Disclaimer - Privacy